Join to view full profile
6400 Fannin StSuite 2800Houston, TX 77030
Phone+1 713-486-8000
Dr. Hsu is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of Texas M D Anderson Cancer CenterFellowship, Neuro-Oncology, 1999 - 2001
New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1996 - 1999
Yale-New Haven Medical CenterInternship, Internal Medicine, 1995 - 1996
The Warren Alpert Medical School of Brown UniversityClass of 1995
Certifications & Licensure
TX State Medical License 2002 - 2028
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Centricity EMR, GE Healthcare, 2013-2017
- CMS Meaningful Use Stage 2 Certification HealtheLife and PowerChart, Cerner Corporation, 2013-2017
- CMS Meaningful Use Stage 2 Certification FairWarning® Patient Privacy Monitoring, FairWarning Technologies, LLC, 2013-2017
Clinical Trials
- A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma
- Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma
- Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy
Publications & Presentations
PubMed
- Phase I trial and pharmacokinetic study of berubicin (RTA 744) in patients with recurrent or refractory high-grade gliomas.Charles A Conrad, Sigmund H Hsu, Neil Thapar, Elizabeth A Maher, Timothy F Cloughesy
Neuro-Oncology Advances. 2026-07-31 - 1 citationsTargeting tGLI1, a novel mediator of tumor therapeutic resistance, using Ketoconazole sensitizes glioblastoma to CDK4/6 therapy and chemoradiation.Yang Yu, Austin Arrigo, Ankush Chandra, Chuling Zhuang, Mariana K Najjar
Biorxiv. 2025-02-26 - 2 citationsThe Use of Apparent Diffusion Coefficient Values for Differentiating Bevacizumab-Related Cytotoxicity from Tumor Recurrence and Radiation Necrosis in Glioblastoma.Kamand Khalaj, Michael A Jacobs, Jay-Jiguang Zhu, Yoshua Esquenazi, Sigmund Hsu
Cancers. 2024-07-02
Journal Articles
- MRI-Guided Radiotherapy for Head and Neck Cancer: Initial Clinical ExperienceM Cao, S Hsu, Y Yang, M L Steinberg, A M Chen, J Lamb, Clinical & translational oncology
Press Mentions
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Moves Closer to IND Filing as Manufacturing of Lead Drug Candidate CommencesOctober 23rd, 2020- Dr. Sigmund Hsu Advances Innovation in Neurosurgery and Cancer NeurologySeptember 17th, 2026
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
